L
Lars Moller Pedersen
Researcher at Odense University Hospital
Publications - 14
Citations - 1853
Lars Moller Pedersen is an academic researcher from Odense University Hospital. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Follicular lymphoma. The author has an hindex of 9, co-authored 14 publications receiving 1708 citations. Previous affiliations of Lars Moller Pedersen include Roskilde University & University of Southern Denmark.
Papers
More filters
Journal ArticleDOI
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more
TL;DR: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
Journal ArticleDOI
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Green,Ken H. Young,Carlo Visco,Zijun Y. Xu-Monette,Attilio Orazi,Ronald S. Go,Ole John Nielsen,Ole V. Gadeberg,Torben Mourits-Andersen,Mikael Frederiksen,Lars Moller Pedersen,Michael Boe Møller +11 more
TL;DR: The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.
Journal ArticleDOI
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Harald Holte,Sirpa Leppä,Magnus Björkholm,Øystein Fluge,Sirkku Jyrkkiö,Jan Delabie,Christer Sundström,Marja-Liisa Karjalainen-Lindsberg,Martin Erlanson,Arne Kolstad,Alexander Fosså,Bjørn Østenstad,Eva Löfvenberg,Marie Nordström,R. Janes,Lars Moller Pedersen,Harald Anderson,Mats Jerkeman,Mikael Eriksson +18 more
TL;DR: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events.
Journal ArticleDOI
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
Gilles Salles,John F. Seymour,Pierre Feugier,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Reda Bouabdallah,John G. Catalano,Brice Pauline,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Bertrand Coiffier,Hervé Tilly +28 more
TL;DR: The effect of rituximab maintenance was consistent among patients subgroups categorized by age, sex, FLIPI score category, induction chemotherapy and response to induction, and found to be consistent among these different subgroups.
Journal ArticleDOI
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
Myron S. Czuczman,Georg Hess,Ole V. Gadeberg,Lars Moller Pedersen,Nancy Goldstein,Ira Gupta,Roxanne C. Jewell,Thomas S. Lin,Steen Lisby,Claus Strange,Kristian Windfeld,Andreas Viardot +11 more
TL;DR: O‐CHOP was safe and efficacious in patients with previously untreated FL, including high‐risk Follicular Lymphoma International Prognostic Index (FLIPI) scores in the 500‐ and 1000‐mg dose groups, respectively.